|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0010068,
umls-concept:C0018802,
umls-concept:C0023779,
umls-concept:C0023820,
umls-concept:C0030705,
umls-concept:C0233820,
umls-concept:C0332281,
umls-concept:C0449432,
umls-concept:C0547047,
umls-concept:C0580822,
umls-concept:C1179435,
umls-concept:C1512612,
umls-concept:C1524073,
umls-concept:C1547300,
umls-concept:C1548760,
umls-concept:C1548799,
umls-concept:C1550594,
umls-concept:C1705117,
umls-concept:C1705248,
umls-concept:C2003888,
umls-concept:C2349179
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-7-28
|
|
pubmed:abstractText |
Very few, if any, studies have assessed the ability of apolipoproteins to predict new-onset of congestive heart failure (HF) in statin-treated patients with coronary heart disease (CHD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1879-1484
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
205
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
522-7
|
|
pubmed:meshHeading |
pubmed-meshheading:19327776-Aged,
pubmed-meshheading:19327776-Coronary Disease,
pubmed-meshheading:19327776-Female,
pubmed-meshheading:19327776-Heart Failure,
pubmed-meshheading:19327776-Humans,
pubmed-meshheading:19327776-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:19327776-Lipids,
pubmed-meshheading:19327776-Lipoproteins,
pubmed-meshheading:19327776-Male,
pubmed-meshheading:19327776-Middle Aged,
pubmed-meshheading:19327776-Models, Statistical,
pubmed-meshheading:19327776-Predictive Value of Tests,
pubmed-meshheading:19327776-Proportional Hazards Models,
pubmed-meshheading:19327776-Risk,
pubmed-meshheading:19327776-Risk Factors,
pubmed-meshheading:19327776-Simvastatin
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).
|
|
pubmed:affiliation |
Centre of Preventive Medicine, Ullevål University Hospital, Oslo, Norway. paul.lane@evidencescisols.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
